CORRESP Filing
Silexion Therapeutics Corp
Date: Sept. 30, 2025 · CIK: 0002022416 · Accession: 0001178913-25-003421
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-290544
Letter
Attention: Jason Drory Silexion Therapeutics Corp Registration Statement on Form S-3 Filed September 26, 2025 SEC File Number 333-290544
Re:
Dear Mr. Drory:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Silexion Therapeutics Corp hereby requests that the effective date of the above-referenced Registration Statement on Form S-3 be accelerated so that it will become effective at 5:00 p.m., Eastern Time on Tuesday, September 30, 2025, or as soon as practicable thereafter.
Please contact Gary Emmanuel, Esq., Greenberg Traurig, LLP, our U.S. legal counsel, at (212) 801‑9337 or Gary.Emmanuel@gtlaw.com , or Jonathan M. Nathan, Adv., Meitar Law Offices, our outside (Israeli) legal counsel, at +972-52-312-5574 or jonathann@meitar.com , with any questions, and please notify either of them when this request for acceleration has been granted.
Sincerely,
/s/ Ilan Hadar
Show Raw Text
CORRESP 1 filename1.htm Silexion Therapeutics Corp 12 Abba Hillel Road Ramat Gan, Israel 5250606 Telephone: +972-3-756-4999 September 30, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Jason Drory Re: Silexion Therapeutics Corp Registration Statement on Form S-3 Filed September 26, 2025 SEC File Number 333-290544 Dear Mr. Drory: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Silexion Therapeutics Corp hereby requests that the effective date of the above-referenced Registration Statement on Form S-3 be accelerated so that it will become effective at 5:00 p.m., Eastern Time on Tuesday, September 30, 2025, or as soon as practicable thereafter. Please contact Gary Emmanuel, Esq., Greenberg Traurig, LLP, our U.S. legal counsel, at (212) 801‑9337 or Gary.Emmanuel@gtlaw.com , or Jonathan M. Nathan, Adv., Meitar Law Offices, our outside (Israeli) legal counsel, at +972-52-312-5574 or jonathann@meitar.com , with any questions, and please notify either of them when this request for acceleration has been granted. Sincerely, /s/ Ilan Hadar Ilan Hadar Chief Executive Officer CC: Mirit Horenshtein Hadar Silexion Therapeutics Corp Gary Emmanuel, Esq. Greenberg Traurig, LLP Jonathan M. Nathan, Adv. Meitar Law Offices